Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00135096 · ClinicalTrials.gov registry record · Phase 3
Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 345
- Enrollment target
NCT00135096 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 345 participants.
The verdict
NCT00135096, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 345 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the change in weight from baseline to study week 52 in the per-protocol population of pre-meal insulin glulisine (Apidra) versus post-meal Apidra, in patients receiving insulin glargine (Lantus) as basal insulin.
Interventions
- DRUG insulin glargine
- DRUG insulin glulisine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2004-08 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00135096
The ClinicalTrials.gov registry entry for NCT00135096 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which insulin glargine is the first listed.
NCT00135096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00135096 about?
NCT00135096 is a clinical study titled "Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin". The purpose of this study is to compare the change in weight from baseline to study week 52 in the per-protocol population of pre-meal insulin glulisine (Apidra) versus post-meal Apidra, in patients receiving insulin glargine (Lantus) as basal insulin.
What is the current status of trial NCT00135096?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 345 participants. The study started on 2004-08. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00135096?
The interventions under investigation include: insulin glargine (DRUG), insulin glulisine (DRUG).
Who is sponsoring clinical trial NCT00135096?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.